Oragenics (OGEN) Announces 1-for-30 Reverse Stock Split
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
May 28, 2025 7:00 AM EDTSARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the Board) on May 27, 2025 approved a One-for-Thirty (1-for-30) reverse stock split of the Companys issued and outstanding shares of common stock, par value $0.001 per share (the Reverse Stock Split). As a result of the Reverse Stock Split, the Companys common stock is expected to begin trading on a split-adjusted basis when the markets open on June 3, 2025.
... More